EA200702445A1 - Соединения тиазола и способы их применения - Google Patents

Соединения тиазола и способы их применения

Info

Publication number
EA200702445A1
EA200702445A1 EA200702445A EA200702445A EA200702445A1 EA 200702445 A1 EA200702445 A1 EA 200702445A1 EA 200702445 A EA200702445 A EA 200702445A EA 200702445 A EA200702445 A EA 200702445A EA 200702445 A1 EA200702445 A1 EA 200702445A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
formula
infectious diseases
methods
administering
Prior art date
Application number
EA200702445A
Other languages
English (en)
Inventor
Суоминг Чжанг
Авинаш Фадке
Куиксиан Лиу
Ксиангчжу Ванг
Джесс Куинн
Давэй Чэн
Венкат Гадхачанда
Шоуминг Ли
Майлинд Дешпенде
Original Assignee
Ачиллион Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ачиллион Фармасьютикалз, Инк. filed Critical Ачиллион Фармасьютикалз, Инк.
Publication of EA200702445A1 publication Critical patent/EA200702445A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем изобретении предлагаются соединения, соли и гидраты формулы Iв которой Ar, R, R, R, r, q и t являются переменными. Некоторые соединения формулы I обладают потенциальной противовирусной активностью. Предлагаются также соединения формулы I, которые представляют собой потенциальные и/или селективные ингибиторы репликации вируса гепатита С. Некоторые соединения, в соответствии с изобретением, ингибируют образование комплекса репликации HCV. Предлагаются также фармацевтические композиции, содержащие одно или более соединений Формулы I, или соль, сольват или ацилированное пролекарство на основе этих соединений, и один или более фармацевтически приемлемых носителей, наполнителей или разбавителей. В соответствии с настоящим изобретением предлагаются методы лечения больных, страдающих от определенных инфекционных болезней, посредством введения им соединений формулы I в эффективных дозах, обеспечивающих уменьшение признаков или симптомов заболевания. Эти инфекционные болезни представляют собой вирусные инфекции, в частности инфекции, вызываемые HCV. В частности, в соответствии с изобретением предлагаются методы лечения людей, страдающих от инфекционных болезней, а также предлагаются методы лечения животных от инфекционных болезней, в том числе скота и домашних животных. Методы лечения включают в себя введение соединения формулы I в качестве единственного активного средства или введение соединения формулы I в сочетании с одним или более другими терапевтическими средствами.
EA200702445A 2005-05-09 2006-05-09 Соединения тиазола и способы их применения EA200702445A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67913305P 2005-05-09 2005-05-09
PCT/US2006/017692 WO2006122011A2 (en) 2005-05-09 2006-05-09 Thiazole compounds and methods of use

Publications (1)

Publication Number Publication Date
EA200702445A1 true EA200702445A1 (ru) 2008-04-28

Family

ID=36968742

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702445A EA200702445A1 (ru) 2005-05-09 2006-05-09 Соединения тиазола и способы их применения

Country Status (18)

Country Link
US (2) US8088806B2 (ru)
EP (1) EP1879575A2 (ru)
JP (1) JP2008540537A (ru)
KR (1) KR20080019213A (ru)
CN (1) CN101247807A (ru)
AP (1) AP2358A (ru)
AU (1) AU2006244203B2 (ru)
BR (1) BRPI0608910A2 (ru)
CA (1) CA2607617A1 (ru)
EA (1) EA200702445A1 (ru)
IL (1) IL186970A0 (ru)
MX (1) MX2007013955A (ru)
NO (1) NO20075723L (ru)
NZ (1) NZ563866A (ru)
SG (1) SG159561A1 (ru)
UA (1) UA92746C2 (ru)
WO (1) WO2006122011A2 (ru)
ZA (1) ZA200709751B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2576036C2 (ru) * 2010-03-17 2016-02-27 Тайвекс Терапьютикс Корпорейшн Модуляторы активности нес1 и способы для них
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1910384T3 (da) * 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
JP2009529059A (ja) * 2006-03-08 2009-08-13 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体
EP2009005A4 (en) 2006-04-19 2010-06-02 Astellas Pharma Inc AZOLECARBOXAMIDE DERIVATIVE
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
WO2008016968A2 (en) * 2006-08-03 2008-02-07 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
AU2007299870A1 (en) 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
WO2008070447A2 (en) * 2006-11-21 2008-06-12 Smithkline Beecham Corporation Anti-viral compounds
CA2672776A1 (en) 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
US7985763B2 (en) 2007-04-10 2011-07-26 National Health Research Institutes Hepatitis C virus inhibitors
EP2148878A4 (en) * 2007-04-20 2011-08-10 Merck Canada Inc NEW HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
EP2164846A2 (en) * 2007-05-22 2010-03-24 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles and their use as antiviral agents.
WO2008141455A1 (en) * 2007-05-23 2008-11-27 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2008154091A1 (en) 2007-06-08 2008-12-18 National Health Research Institutes Thiourea derivatives
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US20100144756A1 (en) * 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
GB2455111A (en) * 2007-11-28 2009-06-03 Addex Pharmaceuticals Sa Metabotropic glutamate receptor (mGluR4) modulators having 5- or 6-membered N-heteroaryl ring substituted by both N-cyclylamino & 5-membered N-heteroaryl ring
CN101801942B (zh) * 2007-07-17 2013-03-27 美国艾森生物科学公司 杂环化合物和作为抗癌剂的用途
CA2693290A1 (en) * 2007-07-20 2009-01-29 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2010534722A (ja) * 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼ活性化薬およびその使用方法
BRPI0815057B8 (pt) * 2007-08-03 2021-05-25 Romark Laboratories Lc composto, composição farmacêutica, e, uso de um composto
US8420642B2 (en) * 2007-10-09 2013-04-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
US8389736B2 (en) * 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
EP2206707B1 (en) 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
EP2070916A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
TWI361808B (en) 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
EP2101173A1 (en) 2008-03-14 2009-09-16 Vivalis In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
US8198284B2 (en) 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
CN102076670B (zh) * 2008-06-24 2013-05-22 Irm责任有限公司 调节g蛋白偶联受体的化合物和方法
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
WO2010009139A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Imidazolyl pyrimidine inhibitor compounds
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
WO2010009155A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Fused heterocyclyc inhibitor compounds
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
JP2011530562A (ja) 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
UA103195C2 (ru) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Производные пурина для применения в лечении аллергий, воспалительных и инфекционных заболеваний
LT2320905T (lt) 2008-08-11 2017-09-11 Glaxosmithkline Llc Naujieji adenino dariniai
US20120040974A1 (en) * 2008-08-18 2012-02-16 Yale University Mif modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
GB0900388D0 (en) 2009-01-12 2009-02-11 Addex Pharmaceuticals Sa New compounds
JP5918124B2 (ja) 2009-05-12 2016-05-18 ロマーク ラボラトリーズ エル．シー． ハロアルキルヘテロアリールベンズアミド化合物
CN102459159A (zh) 2009-06-08 2012-05-16 吉利德科学股份有限公司 烷酰基氨基苯甲酰胺苯胺hdac抑制剂化合物
BRPI1010883A2 (pt) 2009-06-08 2018-07-10 Gilead Sciences Inc compostos inibidores da anilina cicloalquilcarbamato benzamida hdac.
CN101928283A (zh) * 2009-06-25 2010-12-29 上海唐润医药科技有限公司 具有抗hcv活性的化合物及其用途
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
CA2786973C (en) 2010-02-10 2018-04-10 Robert Hermann Gibbon 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
CA2789249A1 (en) * 2010-02-19 2011-08-25 Long Mao Heterocyclic compounds and uses as anticancer agents
WO2012037349A2 (en) * 2010-09-17 2012-03-22 Glaxosmithkline Llc Compounds
WO2012037351A1 (en) * 2010-09-17 2012-03-22 Glaxosmithkline Llc Compounds
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
US8835456B1 (en) 2011-03-18 2014-09-16 Achillion Pharmaceuticals, Inc. NS5A inhibitors useful for treating HCV
CN103097367B (zh) * 2011-04-02 2014-12-03 中国人民解放军军事医学科学院毒物药物研究所 苯丙酸化合物、其制备方法及其医药用途
CN103561739B (zh) 2011-05-27 2016-03-02 艾其林医药公司 可用于治疗hcv感染的经取代的脂肪芬、环芬、异芬、杂芬、杂-异芬以及金属茂
WO2013033037A2 (en) * 2011-08-26 2013-03-07 The Regents Of The University Of California Novel antiprion compounds
SG11201401084TA (en) * 2011-09-30 2014-04-28 Kineta Inc Anti-viral compounds
US20140249154A1 (en) * 2011-10-04 2014-09-04 The Institute for Hepatitis and Virus Research Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
CN104080452A (zh) 2011-10-26 2014-10-01 美国政府健康及人类服务部 用小分子chk2抑制剂治疗hcv感染的方法
US9290489B2 (en) 2012-07-06 2016-03-22 Duke University Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
EP2882726A4 (en) * 2012-08-09 2016-04-06 Neuropore Therapies Inc ARYL AND HETEROARYL-SUBSTITUTED BENZENE DERIVATIVES AS MODULATORS OF PI-3 KINASE SIGNALING PATHWAYS
WO2014063167A1 (en) * 2012-10-19 2014-04-24 The Broad Institute, Inc. Thiazole-based inhibitors of scavenger receptor bi
WO2014063168A1 (en) 2012-10-19 2014-04-24 The Broad Institute, Inc. Heterocycle-bisamide inhibitors of scavenger receptor bl
MX2015010790A (es) * 2013-03-05 2015-11-26 Hoffmann La Roche Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
ES2633987T3 (es) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Derivados de pirido-carboxamidas tricíclicas como inhibidores de ROCK
US9663529B2 (en) 2013-07-02 2017-05-30 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
WO2015050984A1 (en) * 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
JP6452711B2 (ja) 2014-02-20 2019-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ヒトインターフェロンの誘導物質としてのピロロ［３，２］ピリミジン誘導体
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016057518A1 (en) * 2014-10-06 2016-04-14 Kineta, Inc. Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
CA2967248A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
ES2796276T3 (es) * 2015-02-05 2020-11-26 Ab Science Compuestos con actividad antitumoral
EP3262040A4 (en) * 2015-02-27 2018-09-12 The Regents of The University of California Small molecules that enable cartilage rejuvanation
CA2981732C (en) * 2015-04-07 2024-03-12 Boris Khalfin Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
EP3366691A1 (en) 2015-12-03 2018-08-29 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
CN105524056A (zh) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 一种氨基噻唑化合物及其制备方法和应用
EP3419980A4 (en) 2016-02-26 2019-07-03 The Board of Trustees of the Leland Stanford Junior University INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY
CA3019628A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
KR102527786B1 (ko) 2016-04-07 2023-04-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조정제로서 유용한 헤테로시클릭 아미드
CA3020364A1 (en) 2016-04-07 2017-10-12 Duke University Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
KR20190058494A (ko) * 2016-08-26 2019-05-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 모낭 줄기 세포 활성화 및 모발 성장
US10875861B1 (en) 2017-05-26 2020-12-29 Rutgers, The State University Of New Jersey Therapeutic compounds
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
CN111372579B (zh) 2017-10-30 2023-08-22 神经孔疗法股份有限公司 取代的苯基磺酰基苯基三唑硫酮和其用途
WO2019164996A1 (en) 2018-02-21 2019-08-29 Southern Research Institute 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
LT3773589T (lt) 2018-04-03 2024-02-12 Blueprint Medicines Corporation Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US11718593B2 (en) 2018-05-17 2023-08-08 Southern Research Institute 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP3969452A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4139287A1 (en) 2020-04-24 2023-03-01 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
TW202315621A (zh) * 2021-08-25 2023-04-16 美商皮克醫療公司 Ｅｉｆ４ｅ抑制劑及其用途
CN114249702B (zh) * 2022-01-12 2023-09-05 沈阳药科大学 N-芳基-[2,4′-双噻唑]-2′-胺类化合物及其制备与用途
WO2023135330A1 (en) * 2022-01-17 2023-07-20 Centre National De La Recherche Scientifique Deoxycytidine kinase inhibitors

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2474194A (en) * 1941-08-30 1949-06-21 American Cyanamid Co N-heterocyclic substituted guanamines
US3458526A (en) * 1966-09-26 1969-07-29 Upjohn Co Certain 2-amino-4,5-bis(p-methoxyphenyl)thiazoles
US3467666A (en) * 1966-11-07 1969-09-16 Geigy Chem Corp 2-substituted aminothiazoles
BE795907A (fr) * 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
CA1051906A (en) 1973-10-24 1979-04-03 Shionogi And Co. Thiazole derivatives and production thereof
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
JPS6339868A (ja) * 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
DD271258A1 (de) 1988-04-06 1989-08-30 Univ Leipzig Mittel zur chemotherapie von kulturpflanzenvirosen
DE4029771A1 (de) * 1990-09-20 1992-03-26 Basf Ag N-heteroaryl-2-nitroaniline
DE69526958T2 (de) 1994-11-29 2003-01-16 Hisamitsu Pharmaceutical Co., Inc. Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten
SK89398A3 (en) * 1995-12-29 1998-11-04 Boehringer Ingelheim Pharma Phenyl thiazole derivatives with anti herpes virus properties
MY128323A (en) * 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
WO2000006575A2 (en) 1998-07-28 2000-02-10 Smithkline Beecham Plc Azabicyclic compounds
JP2002526482A (ja) * 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
EP1135126A4 (en) 1998-12-07 2003-04-02 Smithkline Beecham Corp MYT1 KINASE INHIBITORS
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7105550B2 (en) 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
WO2001074793A2 (en) 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
WO2002051442A1 (fr) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Co-prescriptions
EP1361220A4 (en) * 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
WO2002094264A1 (en) * 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
HUP0401748A3 (en) * 2001-08-13 2011-03-28 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them
US20040209924A1 (en) 2001-09-26 2004-10-21 Barry Hart Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
WO2003027096A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
US20040236110A1 (en) 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
US20040198773A1 (en) 2001-09-26 2004-10-07 Barry Hart Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
AU2002367752A1 (en) 2001-10-03 2003-11-17 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
CA2462601A1 (en) 2001-10-03 2003-04-10 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US20030158199A1 (en) 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
US6919294B2 (en) 2002-02-06 2005-07-19 Japan Energy Corporation Method for preparing hydrogenation purification catalyst
PT1525200E (pt) 2002-08-02 2008-01-10 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças
EP1539722A1 (en) * 2002-08-07 2005-06-15 F. Hoffmann-La Roche Ag Thiazole derivatives
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
MXPA05008450A (es) * 2003-02-10 2005-10-18 Vertex Pharma Procesos para la preparacion de n-heteroaril-n-aril-aminas mediante reaccion de un ester de acido n-aril-carbamico con un halo-heteroarilo y procesos analogos.
CA2515215A1 (en) 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1594847A2 (en) 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
BRPI0407456A (pt) * 2003-02-12 2006-01-31 Pfizer Derivados antiproliferativos de 2-(sulfo-fenil)-aminotiazole e composições farmacêuticas, e métodos para o seu uso
CA2517308A1 (en) 2003-02-27 2004-09-10 Ab Science Tailored treatment suitable for different forms of mastocytosis
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
BRPI0409429A (pt) 2003-04-15 2006-04-18 Pfizer ácido carboxìlico substituìdo na posição alfa como moduladores ppar
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
EP1624873A2 (en) 2003-04-28 2006-02-15 AB Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
WO2004098612A2 (en) 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
US7652044B2 (en) 2003-06-03 2010-01-26 Novartis A.G. P-38 inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1653934B1 (en) 2003-08-15 2008-05-14 AB Science Use of c-kit inhibitors for treating type ii diabetes
US20080234288A1 (en) 2003-09-30 2008-09-25 Kenneth Alan Simmen Hcv Inhibiting Sulfonamides
EP1686949A2 (en) * 2003-11-24 2006-08-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
CA2554925A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005232753A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycylic thiazoles as potassium ion channel modulators
WO2005102325A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
WO2005102318A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
JP2007533732A (ja) 2004-04-23 2007-11-22 アブ サイエンス 線維症を処置するためのｃ−ｋｉｔ阻害剤の使用法
WO2005102326A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
US20080004279A1 (en) 2004-04-23 2008-01-03 Alain Moussy Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases
CA2566104A1 (en) 2004-05-18 2005-12-01 Ab Science Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
WO2005115385A1 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
MX2007003377A (es) 2004-09-23 2007-05-10 Pfizer Prod Inc Agonistas del receptor de trombopoyetina.
MX2007014048A (es) 2005-05-11 2008-02-05 Abbott Lab Antagonistas del receptor vaniloide subtipo 1 (vr1) y usos de los mismos.
CA2641766A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2009529059A (ja) * 2006-03-08 2009-08-13 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体
EP2164846A2 (en) * 2007-05-22 2010-03-24 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles and their use as antiviral agents.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2576036C2 (ru) * 2010-03-17 2016-02-27 Тайвекс Терапьютикс Корпорейшн Модуляторы активности нес1 и способы для них
US9409902B2 (en) 2010-03-17 2016-08-09 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor

Also Published As

Publication number Publication date
EP1879575A2 (en) 2008-01-23
AU2006244203B2 (en) 2012-05-03
MX2007013955A (es) 2008-02-05
AP2007004268A0 (en) 2007-12-31
US20070004711A1 (en) 2007-01-04
NZ563866A (en) 2011-03-31
BRPI0608910A2 (pt) 2010-02-17
SG159561A1 (en) 2010-03-30
WO2006122011A3 (en) 2007-05-03
IL186970A0 (en) 2008-02-09
US20120108576A1 (en) 2012-05-03
US8088806B2 (en) 2012-01-03
WO2006122011A2 (en) 2006-11-16
NO20075723L (no) 2008-02-05
CA2607617A1 (en) 2006-11-16
AU2006244203A1 (en) 2006-11-16
KR20080019213A (ko) 2008-03-03
UA92746C2 (en) 2010-12-10
AP2358A (en) 2012-01-30
ZA200709751B (en) 2008-11-26
JP2008540537A (ja) 2008-11-20
CN101247807A (zh) 2008-08-20

Similar Documents

Publication Publication Date Title
EA200702445A1 (ru) Соединения тиазола и способы их применения
EA200602130A1 (ru) Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов
NO20062928L (no) Azabenzofuran substituerte tiourear som inhibitorer av viral replikasjon
MXPA05005379A (es) Tioureas de arilo sustituidas y compuestos relacionados; inhibidores de duplicacion viral.
WO2005095345A3 (en) Heteroaryl guanidines as inhibitors of viral replication
CL2023000167A1 (es) Péptidos funcionalizados como agentes antivirales
CO2021008055A2 (es) Heterociclos funcionalizados como agentes antivirales
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA201201031A1 (ru) Ингибиторы вируса гепатита с
CY1109748T1 (el) Κινοξαλινυλ μακροκυκλικοι αναστολεις πρωτεασης σερινης ηπατιτιδας c
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
EA201391519A1 (ru) 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
MY155851A (en) Quinoxaline-containing compounds as hepatitis c virus inhibitors
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
RU2013119607A (ru) Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
RU2014122154A (ru) Композиции, пригодные для лечения вирусных заболеваний
EA200500610A1 (ru) Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridae
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
RU2015114543A (ru) Способы лечения гепатита с
RU2011111117A (ru) Лечение аутоиммунных заболеваний
EA200700433A1 (ru) Производные бетулинола в качестве агентов против вич (вируса иммунодефицита человека)